Joseph Butchart, Laura Brook, Vivienne Hopkins, Jessica Teeling, Ursula Püntener, David Culliford, Richard Sharples, Saif Sharif, Brady McFarlane, Rachel Raybould, Rhodri Thomas, Peter Passmore, V Hugh Perry, Clive Holmes
OBJECTIVES: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. METHODS: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period...
May 26, 2015: Neurology